Multiple myeloma is a largely incurable tumor disease that develops from a premalignant precursor and whose mechanisms of development are not yet fully understood. In a large-scale proteomics study, researchers led by Astrid Slany from the Faculty of Chemistry at the University of Vienna have now compared tumour cells in various stages - from the MGUS precursor to advanced multiple myeloma - and identified mechanisms that lead to disease progression. Her study was recently published in the journal "Molecular and Cellular Proteomics".

Press release in German: Nährboden für Tumorentwicklung charakterisiert (2. Mai 2019)

Lukas Janker, Rupert L. Mayer, Andrea Bileck, Dominique Kreutz, Johanna C. Mader, Kirsten Utpatel, Daniel Heudobler, Hermine Agis, Christopher Gerner and Astrid Slany: Metabolic, anti-apoptotic and immune evasion strategies of primary human myeloma cells indicate adaptations to hypoxia. In: Molecular and Cellular Proteomics, 2019.
DOI: https://doi.org/10.1074/mcp.RA119.001390